NEXGEL, INC. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Adam Levy replaced as CEO by Brian Kieser (effective Aug 21, 2026). Board formed Special Committee to review operations, assets, liquidity, and capital structure over 30-45 days. Levy receives separation benefits (unspecified) plus 90 days unpaid transition assistance. No financial figures disclosed. Company will evaluate divestiture of non-core assets and focus on BioNX Surgical, BioNX Regenerative Eye Health, and hydrogel tech.
Why this rating
CEO forced out amid liquidity stress; strategic review signals distress. Material for $11M market-cap company but no bankruptcy/going-concern disclosed yet.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.